US 12,390,475 B2
Dry powder treprostinil for the treatment of pulmonary hypertension
Robert Frank Roscigno, Melbourne Beach, FL (US); Brian T. Farrer, Apex, NC (US); Jacob J. Sprague, Cary, NC (US); and Benjamin Maynor, Durham, NC (US)
Assigned to LIQUIDIA TECHNOLOGIES, INC., Morrisville, NC (US)
Filed by LIQUIDIA TECHNOLOGIES, INC., Morrisville, NC (US)
Filed on Jul. 12, 2023, as Appl. No. 18/350,926.
Application 18/350,926 is a continuation of application No. 17/390,514, filed on Jul. 30, 2021, granted, now 11,744,836.
Application 17/390,514 is a continuation of application No. 17/104,348, filed on Nov. 25, 2020, granted, now 11,712,442.
Application 17/104,348 is a continuation of application No. 16/099,135, granted, now 10,898,494, issued on Jan. 26, 2021, previously published as PCT/US2017/031301, filed on May 5, 2017.
Claims priority of provisional application 62/472,204, filed on Mar. 16, 2017.
Claims priority of provisional application 62/440,078, filed on Dec. 29, 2016.
Claims priority of provisional application 62/404,960, filed on Oct. 6, 2016.
Claims priority of provisional application 62/332,013, filed on May 5, 2016.
Prior Publication US 2023/0346799 A1, Nov. 2, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/00 (2006.01); A61K 9/48 (2006.01); A61K 31/557 (2006.01); A61K 31/5575 (2006.01); A61P 9/12 (2006.01); A61K 47/02 (2006.01); A61K 47/18 (2017.01); A61K 47/26 (2006.01)
CPC A61K 31/557 (2013.01) [A61K 9/0075 (2013.01); A61K 9/4858 (2013.01); A61K 31/5575 (2013.01); A61P 9/12 (2018.01); A61K 47/02 (2013.01); A61K 47/183 (2013.01); A61K 47/26 (2013.01)] 20 Claims
 
1. A system for administrating treprostinil or a pharmaceutically acceptable salt thereof to a patient, the system comprising:
a dosage unit containing a predetermined amount of dry powder particles having a mass median aerodynamic diameter between 1 μm and 5 μm and a fine particle fraction between 82 percent and 89 percent of the predetermined amount of dry powder particles, the dry powder particles comprising:
an excipient matrix; and
treprostinil or a pharmaceutically acceptable salt thereof; and
a dry powder inhaler comprising:
a body configured to receive the dosage unit; and
a mouthpiece that is moveable with respect to the body to an aligned position,
wherein the dry powder inhaler allows delivery of the dry powder particles from the dosage unit through the mouthpiece to the patient via inhalation over one to two breaths when the mouthpiece is in the aligned position.